6-[2,3-di(hexadecanoyloxy)propoxy]-2-(1H-imidazol-5-ylmethyl)-4,6-dioxohexanoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油脂
• 英文名称: 6-[2,3-di(hexadecanoyloxy)propoxy]-2-(1H-imidazol-5-ylmethyl)-4,6-dioxohexanoic acid
• 化学式: C₄₅H₇₈N₂O₉
• 分子量: 791.1
• InChiKey: ZMOCIHBGNUQGKA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  14.1
• 重原子数：
  56
• 可旋转键数：
  43
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  162
• 氢给体数：
  2
• 氢受体数：
  10

文献信息

• Dosing and Administration of Oligonucleotide Cancer Therapies
  申请人：PRONAI THERAPEUTICS, INC.

  公开号：US20150272980A1

  公开（公告）日：2015-10-01

  The present invention relates to cancer therapies, compositions, and methods of using the same. In particular, the present invention provides methods of dosing and administration of cancer therapies comprising the administration of oligomers and liposome formulations of oligomers, wherein the cancer is mediated by the bcl-2 oncogene. In some aspects, the oligomers or liposome formulations of oligomers are administered in combination with one or more other therapeutic agents.
• Methods of Using Biomarkers for the Treatment of Cancer by Modulation of BCL2 Expression
  申请人：PRONAI THERAPEUTICS, INC.

  公开号：US20150299803A1

  公开（公告）日：2015-10-22

  The present invention relates to cancer therapies and methods of using the same. In particular, the present invention provides methods of monitoring and improving the administration of cancer therapies, wherein the cancer is mediated by the BCL2 oncogene, via markers of disease identification, disease progression, drug resistance, and/or treatment efficacy.
• [EN] DOSING AND ADMINISTRATION OF OLIGONUCLEOTIDE CANCER THERAPIES<br/>[FR] DÉTERMINATION DE DOSE ET ADMINISTRATION DE THÉRAPIES ANTICANCÉREUSES OLIGONUCLÉOTIDIQUES
  申请人：PRONAI THERAPEUTICS INC

  公开号：WO2014071379A1

  公开（公告）日：2014-05-08

  The present invention relates to cancer therapies, compositions, and methods of using the same. In particular, the present invention provides methods of dosing and administration of cancer therapies comprising the administration of oligomers and liposome formulations of oligomers, wherein the cancer is mediated by the bcl-2 oncogene. In some aspects, the oligomers or liposome formulations of oligomers are administered in combination with one or more other therapeutic agents.
• [EN] METHODS OF USING BIOMARKERS FOR THE TREATMENT OF CANCER BY MODULATION OF BCL2|EXPRESSION<br/>[FR] MÉTHODES D'UTILISATION DE BIOMARQUEURS POUR LE TRAITEMENT DU CANCER PAR MODULATION DE L'EXPRESSION DE BCL2
  申请人：PRONAI THERAPEUTICS INC

  公开号：WO2014071406A1

  公开（公告）日：2014-05-08

  The present invention relates to cancer therapies and methods of using the same. In particular, the present invention provides methods of monitoring and improving the administration of cancer therapies, wherein the cancer is mediated by the BCL2 oncogene, via markers of disease identification, disease progression, drug resistance, and/or treatment efficacy.